SG11202108519TA - Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia - Google Patents
Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomiaInfo
- Publication number
- SG11202108519TA SG11202108519TA SG11202108519TA SG11202108519TA SG11202108519TA SG 11202108519T A SG11202108519T A SG 11202108519TA SG 11202108519T A SG11202108519T A SG 11202108519TA SG 11202108519T A SG11202108519T A SG 11202108519TA SG 11202108519T A SG11202108519T A SG 11202108519TA
- Authority
- SG
- Singapore
- Prior art keywords
- thioeno
- pyridin
- amine compounds
- familial dysautonomia
- treating familial
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805283P | 2019-02-13 | 2019-02-13 | |
| PCT/US2020/017430 WO2020167628A1 (en) | 2019-02-13 | 2020-02-10 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108519TA true SG11202108519TA (en) | 2021-09-29 |
Family
ID=69960696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108519TA SG11202108519TA (en) | 2019-02-13 | 2020-02-10 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220135586A1 (es) |
| EP (1) | EP3924049A1 (es) |
| JP (1) | JP2022520822A (es) |
| KR (1) | KR20210137040A (es) |
| CN (1) | CN113795304A (es) |
| AU (1) | AU2020222881A1 (es) |
| BR (1) | BR112021015853A2 (es) |
| CA (1) | CA3129067A1 (es) |
| CL (1) | CL2021002137A1 (es) |
| CO (1) | CO2021010598A2 (es) |
| EA (1) | EA202192170A1 (es) |
| IL (1) | IL285399A (es) |
| MX (1) | MX2021009667A (es) |
| PE (1) | PE20220139A1 (es) |
| SG (1) | SG11202108519TA (es) |
| WO (1) | WO2020167628A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3182912A1 (en) | 2020-05-13 | 2021-11-18 | Chdi Foundation, Inc. | Htt modulators for treating huntington's disease |
| US20240092800A1 (en) * | 2021-01-14 | 2024-03-21 | Georgetown University | Usp13 inhibitors and methods of use thereof |
| CN112920053B (zh) * | 2021-02-01 | 2022-07-01 | 暨明医药科技（苏州）有限公司 | 一种手性α-甲基芳乙胺的制备方法 |
| US20240043444A1 (en) * | 2021-02-05 | 2024-02-08 | Ptc Therapeutics, Inc. | Methods for treating spinocerebellar ataxia type 3 |
| EP4288054A1 (en) * | 2021-02-05 | 2023-12-13 | PTC Therapeutics, Inc. | Methods for treating spinocerebellar ataxia type 3 |
| TW202313623A (zh) | 2021-06-03 | 2023-04-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 具有整合酶抑制活性的吡啶酮化合物及其藥用用途 |
| WO2023039369A1 (en) * | 2021-09-07 | 2023-03-16 | Ptc Therapeutics, Inc. | Methods for treating neurogenerative diseases |
| WO2023081857A1 (en) | 2021-11-04 | 2023-05-11 | Skyhawk Therapeutics, Inc. | Condensed pyridazine amine derivatives treating sca3 |
| WO2023212239A1 (en) | 2022-04-27 | 2023-11-02 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| WO2023220433A1 (en) * | 2022-05-12 | 2023-11-16 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| WO2023250316A1 (en) * | 2022-06-22 | 2023-12-28 | Ptc Therapeutics, Inc. | Compounds for treating spinocerebellar ataxia type 3 |
| WO2024036143A2 (en) * | 2022-08-09 | 2024-02-15 | Ptc Therapeutics, Inc. | Methods for modulating rna splicing |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015005491A1 (ja) * | 2013-07-12 | 2015-01-15 | 国立大学法人京都大学 | 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法 |
| ES2928714T3 (es) | 2015-01-16 | 2022-11-22 | Massachusetts Gen Hospital | Compuestos para mejorar el empalme del ARNm |
-
2020
- 2020-02-10 SG SG11202108519TA patent/SG11202108519TA/en unknown
- 2020-02-10 CN CN202080028449.2A patent/CN113795304A/zh active Pending
- 2020-02-10 WO PCT/US2020/017430 patent/WO2020167628A1/en unknown
- 2020-02-10 CA CA3129067A patent/CA3129067A1/en active Pending
- 2020-02-10 EA EA202192170A patent/EA202192170A1/ru unknown
- 2020-02-10 PE PE2021001329A patent/PE20220139A1/es unknown
- 2020-02-10 US US17/430,511 patent/US20220135586A1/en active Pending
- 2020-02-10 JP JP2021547446A patent/JP2022520822A/ja active Pending
- 2020-02-10 KR KR1020217028864A patent/KR20210137040A/ko not_active Application Discontinuation
- 2020-02-10 AU AU2020222881A patent/AU2020222881A1/en active Pending
- 2020-02-10 EP EP20714017.9A patent/EP3924049A1/en active Pending
- 2020-02-10 MX MX2021009667A patent/MX2021009667A/es unknown
- 2020-02-10 BR BR112021015853-7A patent/BR112021015853A2/pt unknown
-
2021
- 2021-08-05 IL IL285399A patent/IL285399A/en unknown
- 2021-08-12 CO CONC2021/0010598A patent/CO2021010598A2/es unknown
- 2021-08-12 CL CL2021002137A patent/CL2021002137A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA202192170A1 (ru) | 2021-11-15 |
| EP3924049A1 (en) | 2021-12-22 |
| MX2021009667A (es) | 2021-12-10 |
| JP2022520822A (ja) | 2022-04-01 |
| AU2020222881A1 (en) | 2021-09-09 |
| CO2021010598A2 (es) | 2021-08-30 |
| BR112021015853A2 (pt) | 2021-10-05 |
| IL285399A (en) | 2021-09-30 |
| CA3129067A1 (en) | 2020-08-20 |
| PE20220139A1 (es) | 2022-01-27 |
| CN113795304A (zh) | 2021-12-14 |
| US20220135586A1 (en) | 2022-05-05 |
| CL2021002137A1 (es) | 2022-02-25 |
| KR20210137040A (ko) | 2021-11-17 |
| WO2020167628A1 (en) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285399A (en) | Thiano[2,3-b]pyridine-7-amine compounds for the treatment of familial dysautonomia | |
| IL276802B1 (en) | Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones | |
| IL289290A (en) | Substituted benzyltriazole compounds for cbl-b inhibition, and other uses thereof | |
| IL287726A (en) | aromatic compounds | |
| IL291565A (en) | A method for treating phenylalanine irregularity | |
| IL280661A (en) | PYRROLO[2,3-B]PYRIDINE is mutated at position 4 as ERBB regulators that are useful in cancer therapy | |
| IL289416A (en) | Tricyclic compound, its preparation method and use | |
| EP3999523A4 (en) | MELANOPHILIN ANTISENSE OLIGONUCLEOTIDES | |
| SG11202111382RA (en) | Antibacterial agents & methods | |
| EP3801510A4 (en) | METHODS OF TREATMENT OF MUSCULAR DYSTROPHIES | |
| IL285204A (en) | Formulation of apavicin, method for its preparation | |
| GB202005952D0 (en) | Regalsystem, RegaLseitenwand und Seitenwandteil | |
| EP3946287A4 (en) | METHOD OF TREATMENT OF CANCER WITH TOZADENANT | |
| EP3789023A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH A COGNITIVE DISORDER, CONTAINING MUMEFURAL | |
| IL288797A (en) | Treatment of synoclinopathy | |
| EP4076669A4 (en) | METHOD FOR TREATING GLIOBLASTOMA | |
| IL289141A (en) | Compounds 7,8 dihydro-4h-pyrazolo[3,4-c]azepin-6-one | |
| EP3806814A4 (en) | PHOTO STABILIZATION COMPOUNDS, COMPOSITIONS, AND PROCEDURES | |
| EP3699287A4 (en) | 1,5-DIAMINOPENTANE PURIFICATION PROCESS | |
| PT3921026T (pt) | Carotenoides c50 para o tratamento ou a prevenção da náusea | |
| GB201902409D0 (en) | Process for polymerizing 1,3-benzoxazines | |
| IL284668A (en) | Methods of treating schizophrenia | |
| IL290319A (en) | Compound for combined treatment | |
| IL289708A (en) | Immuno-oncology treatment using isoflavone compounds | |
| IL286015A (en) | A process for preparing tricyclic substances and intermediates obtained in this process |